|Mr. Robert B. Kay||Exec. Chairman & CEO||314.9k||N/A||1940|
|Mr. Robert L. Erwin||Pres||251.67k||N/A||1953|
|Mr. James P. Mullaney CPA, CPA||Chief Financial Officer||240k||N/A||1971|
|Mr. Terence E. Ryan||Chief Scientific Officer||200k||N/A||1955|
|Dr. Renato Lobo||Chief Medical Officer||N/A||N/A||N/A|
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
iBio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.